Our Treatments
Our treatments
Creating Better Treatments and Changing Lives
EPM is committed to developing a series of new therapeutic solutions based on cannabinoid acids which provide alternative treatments for patients. This is the driving force behind EPM’s research program. Although cannabinoid acids are potential treatments for a wide range of diseases, currently, EPM focuses on two main therapeutic conditions based on its lead molecules: metabolic disorders (Prader-Willi Syndrome) and inflammatory skin disease (Psoriasis).
Our Treatments
Prader-Willi Syndrome
Selected formulation
Oral
Expected clinical trail timeline
Phase 1 clinical trial anticipated in H1 2023
EPM’s Potential Solution
Results demonstrated that treatment with EPM301 in preclinical study on a mouse model, has reduced food intake and body weight, improved ambulatory activity, normalized lipid, glucose and insulin levels and more. These results give promise to a drug based on EPM301 which will be able to regulate hunger in PWS people, as well as improve metabolic systems homeostasis.
Our treatments
Psoriasis
Selected formulation
Topical
Expected clinical trail timeline
Phase 1 clinical trail in healthy volunteers anticipated during 2023
EPM's potential solution
The treatment is based on EPM301 and has been evaluated in an ex vivo model of inflammatory skin disease. When applied topically, it displayed similar activity to hydrocortisone.
Our Treatments
Inflammatory Bowel Disease
Selected formulation
Oral
Expected clinical trail timeline
TBD
EPM's potential solution
The treatment is based on EPM301 and has been evaluated in both acute (DSS induced mouse colitis) and chronic (IL-10 knock-out mouse) animal models of IBD and has shown similar activity to prednisone (acute model) and anti-TNFa mAb (chronic model) when administered by gavage.